1,25(OH)2D3 ADMINISTRATION IN MODERATE RENAL-FAILURE - A PROSPECTIVE DOUBLE-BLIND TRIAL

被引：165
作者：
BAKER, LRI
ABRAMS, SML
ROE, CJ
FAUGERE, MC
FANTI, P
SUBAYTI, Y
MALLUCHE, HH
机构：
[1] UNIV KENTUCKY,MED CTR,DIV NEPHROL BONE & MINERAL METAB,800 ROSE ST,LEXINGTON,KY 40536
[2] ST BARTHOLOMEWS HOSP,DEPT NEPHROL,LONDON EC1A 7BE,ENGLAND
[3] ST BARTHOLOMEWS HOSP,DEPT CLIN PHARMACOL,LONDON EC1A 7BE,ENGLAND
来源：
KIDNEY INTERNATIONAL | 1989年 / 35卷 / 02期
关键词：
D O I：
10.1038/ki.1989.36
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：661 / 669
页数：9
相关论文
共 32 条
[1]  
BAKER LRI, 1986, CLIN NEPHROL, V26, P185
[2]  
BIKLE D, 1983, ASSAY CALCIUM REGULA
[3]   DETERMINANTS OF SERUM 1,25(OH)2D LEVELS IN RENAL-DISEASE [J].
CHEUNG, AK ;
MANOLAGAS, SC ;
CATHERWOOD, BD ;
MOSELY, CA ;
MITAS, JA ;
BLANTZ, RC ;
DEFTOS, LJ .
KIDNEY INTERNATIONAL, 1983, 24 (01) :104-109
[4]  
CHRISTIANSEN C, 1978, LANCET, V2, P700
[5]   IS 1,25-DIHYDROXY-CHOLECALCIFEROL HARMFUL TO RENAL-FUNCTION IN PATIENTS WITH CHRONIC-RENAL-FAILURE [J].
CHRISTIANSEN, C ;
RODBRO, P ;
CHRISTENSEN, MS ;
HARTNACK, B .
CLINICAL ENDOCRINOLOGY, 1981, 15 (03) :229-236
[6]   BONE GLA PROTEIN IN PREDIALYSIS CHRONIC-RENAL-FAILURE - EFFECTS OF 1,25(OH)2D3 ADMINISTRATION IN A LONG-TERM FOLLOW-UP [J].
COEN, G ;
MAZZAFERRO, S ;
BONUCCI, E ;
TAGGI, F ;
BALLANTI, P ;
BIANCHI, AR ;
DONATO, G ;
MASSIMETTI, C ;
SMACCHI, A ;
CINOTTI, GA .
KIDNEY INTERNATIONAL, 1985, 28 (05) :783-790
[7]  
HEALY MD, 1980, ARCH INTERN MED, V14, P1030
[8]  
LEVINE BS, 1985, J LAB CLIN MED, V105, P239
[9]  
Lillie R.D., 1976, HISTOPATHOLOGIC TECH, V4th
[10]  
LUCAS PA, 1985, P EUR DIAL TRANSPLAN, V22, P1124
1234